Corona Remedies
Corona Remedies
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has delivered good profit growth of 23.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
- Company has been maintaining a healthy dividend payout of 29.4%
Weaknesses
2- Stock is trading at 18.3 times its book value
- Company might be capitalizing the interest cost
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 33d agoCorona Remedies Ltd is a healthcare company with a market cap of ₹12,668 Cr trading at a PE of 64x and 17.05x book value. The company has delivered compounded profit growth of 23% CAGR over 5 years with ROE of 30% in the last year, but its valuation multiples are significantly elevated relative to earnings and book value.
- Strong profit growth of 33% CAGR over the last 3 years indicates accelerating earnings momentum
- Last year ROE of 30% demonstrates efficient capital utilization and high-quality earnings generation
- 5-year compounded sales growth of 19% reflects consistent top-line expansion and demand for products
- 3-year ROE of 26% sustained over multiple years shows this is not a one-off performance spike
- TTM sales growth of 18% indicates continued revenue momentum in the most recent period
- TTM profit growth of 28% outpaces sales growth of 18%, suggesting improving operating leverage and margin expansion
- Healthy dividend payout of 29.4% shows management commitment to returning capital to shareholders
- 5-year ROE of 22% provides a long-term track record of generating above-average returns on equity
- PE ratio of 64x is extremely elevated, pricing in substantial future growth and leaving little margin of safety
- Price-to-book ratio of 17.05x means investors are paying a very steep premium over net asset value
- Company might be capitalizing interest costs, which could overstate reported profitability and asset values
- Dividend yield of just 0.48% offers minimal income return relative to the high valuation being paid
- At 64x PE, even a slight deceleration in the 33% profit CAGR could trigger significant multiple compression
- Absence of disclosed debt-to-equity ratio limits visibility into the company's leverage and financial risk profile
- 10-year growth data is unavailable for sales, profit, and stock CAGR, making long-term consistency difficult to assess
- 52-week high and low data are unavailable, reducing ability to gauge recent price volatility and trading range
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 28d ago- Q1 profit surges 30% Aug 3
Net profit rose 30.1% YoY to ₹60.1 crore on revenue of ₹422.4 crore (up 21.9%), with EBITDA margin expanding to 22.04% from 20.49%.
- Rank climbs to 26th in IPM Aug 3
Corona Remedies moved up to 26th rank in the India Prescription Market and inaugurated an EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad.
- Active investor engagement Aug 10
Company attending Emkay and Equirus investor conferences on Aug 13-14, signalling proactive outreach to institutional investors.
- Q1FY27 earnings call posted Aug 3
Audio recording of the Q1 FY27 earnings conference call for the quarter ended June 30, 2026 was made available on the company website per SEBI Regulation 30.
- Analyst call scheduled Jul 22
Corona Remedies announced a Q1FY27 analyst call on August 3, 2026, led by the MD, JMD, and CFO.
TL;DR: Corona Remedies delivered a strong Q1FY27 with 30% profit growth, healthy margin expansion, and improved market ranking. No identifiable headwinds emerged in the period. The new EU-GMP facility and rising IPM rank suggest the growth trajectory is intact, and active investor engagement points to confidence in near-term momentum.
Quarterly Results
| Particulars | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other Income | 2 | 1 | 1 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| PBT | 57 | 58 | 43 | 61 | 70 | 55 | 54 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net Profit | 43 | 45 | 31 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 | 9.83 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Expenses | 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,109 | 1,162 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 294 | 317 |
| OPM % | 13% | 15% | 18% | 2.9% | 14% | 15% | 20% | 21% | 21% |
| Other Income | 3 | 3 | 5 | 7 | 7 | 5 | 5 | -9 | -7 |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 | 42 |
| PBT | 54 | 77 | 92 | -1 | 111 | 118 | 198 | 240 | 260 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% | 23% | — |
| Net Profit | 35 | 59 | 70 | 0 | 85 | 90 | 149 | 185 | 199 |
| EPS in Rs | 74.85 | 127 | 151 | -0.08 | 13.85 | 14.8 | 24.37 | 30.22 | 32.47 |
| Div. Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% | 33% | — |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 685 |
| Borrowings | 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 |
| Other Liabilities | 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| Fixed Assets | 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 | 25 |
| Other Assets | 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 |
| Investing | -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 |
| Financing | 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 56 |
| CFO/OP | 49 | 65 | 101 | 557 | 100 | 112 | 97 | 95 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 | 38 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 | 175 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 | 7 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 | -15 |
| ROCE % | — | 30% | 27% | 1% | 29% | 25% | 31% | 33% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Corona Remedies insights
63 extracted metrics + investor summaries across FY19–FY27.
Documents
Frequently Asked Questions about Corona Remedies
What does Corona Remedies Ltd do?
Where is Corona Remedies Ltd (CORONA) listed?
Which sector does Corona Remedies Ltd belong to?
What is the market capitalisation of Corona Remedies Ltd?
What is the PE ratio of Corona Remedies Ltd?
What is the 52-week high and low of Corona Remedies Ltd?
Does Corona Remedies Ltd pay dividends?
What is the Return on Equity (ROE) of Corona Remedies Ltd?
Company Information
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CORONA.md for Corona Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.